HID-HSCT Versus IST as First-line Treatment for SAA

Exclusion criteria

• ✕. Inherited bone marrow failure syndromes (IBMFS), including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome (SDS), etc.;
• ✕. Clonal cytogenetic abnormalities or bone marrow examination suggesting pre-MDS or MDS;
• ✕. Known severe allergy to ATG;
• ✕. Previous allogeneic or autologous hematopoietic stem cell transplantation;
• ✕. Previous solid organ transplantation;
• ✕. Uncontrolled infection at enrollment, or requiring mechanical ventilation or hemodynamic instability;
• ✕. Active HIV replication at enrollment, detectable HCV antibody positivity and HCV-RNA positivity within 90 days prior to enrollment, or HBsAg positivity; known seropositivity for HIV or active hepatitis C virus;
• ✕. History of malignant tumors (except resected basal cell carcinoma or treated cervical carcinoma in situ);